What biomarker tests are recommended for MDS

Biomarker Testing Recommendations for MDS

Great question! Understanding what tests your doctors recommend is an important part of managing MDS. Let me walk you through the key biomarker tests that are standard in MDS evaluation.

What Tests Are Recommended

According to the NCCN Guidelines for Myelodysplastic Syndromes (Version 1.2026), biomarker testing for MDS includes:

1. Genetic/Molecular Testing (Most Important)

Your doctors will typically order next-generation sequencing (NGS) or gene panel testing to look for mutations in frequently mutated MDS genes. Here are the key genes they screen for:

High-Impact Genes (associated with prognosis):

• TP53 – Associated with poor prognosis; important for treatment decisions
• ASXL1 – Independently linked to poor prognosis
• RUNX1 – Associated with poor prognosis
• EZH2 – Associated with poor prognosis
• BCOR and BCORL1 – Associated with poor prognosis
• SRSF2, U2AF1, ZRSR2 – Splicing factor mutations; associated with poor prognosis

Favorable Prognosis Genes:

• SF3B1 – Strongly associated with ring sideroblasts (abnormal iron-containing cells); linked to more favorable prognosis

Other Commonly Tested Genes:

• TET2, DNMT3A, STAG2, NRAS, CBL, NF1, IDH1, IDH2, SETBP1, PHF6, WT1, and others

According to NCCN Guidelines, these mutations help doctors understand your disease and predict how it might progress.

2. Cytogenetic Testing (Chromosome Analysis)

Your bone marrow sample will be analyzed for:

• Karyotype – Shows the structure and number of chromosomes
• Fluorescence in situ hybridization (FISH) – Detects specific chromosome changes
• Chromosome microarray – Identifies small deletions or duplications

Common findings include del(5q), del(7q), and complex karyotypes, which affect treatment options and prognosis.

3. Flow Cytometry

This test analyzes blood and bone marrow cells to:

• Count different cell types
• Detect abnormalities in cell development
• Screen for PNH clones (a specific type of cell abnormality)

4. Blood Count Tests (CBC)

Regular complete blood counts measure:

• Hemoglobin (red blood cells)
• White blood cells
• Platelets
• Blast percentage (immature cells)

These help monitor disease progression and treatment response.

5. Bone Marrow Evaluation

Your doctor will examine:

• Blast percentage – The number of immature cells (important for classification)
• Dysplasia – Abnormal cell development
• Ring sideroblasts – Iron-containing cells (especially relevant if SF3B1 mutation is present)
• Iron stain – Shows iron storage in cells

Why These Tests Matter

According to NCCN Guidelines, biomarker testing serves several purposes:

1. Confirms MDS diagnosis – Mutations and cytogenetic changes help establish the diagnosis
2. Predicts prognosis – Certain mutations indicate how quickly the disease might progress
3. Guides treatment decisions – Specific mutations may qualify you for targeted therapies:
   • IDH1 mutations → Ivosidenib may be considered
   • IDH2 mutations → Enasidenib may be considered
   • SF3B1 mutations → May influence treatment approach
4. Monitors disease progression – Repeat testing helps track changes over time

Important Context: IPSS-M Scoring

The NCCN Guidelines reference the IPSS-M (Integrated Prognostic Scoring System), which combines:

• Genetic mutations (16 main effect genes)
• Cytogenetic findings
• Blood count values

This comprehensive scoring helps your doctor determine your risk category (very low, low, intermediate, high) and recommend appropriate treatment.

Questions to Ask Your Healthcare Team

Since biomarker testing is complex, here are helpful questions:

1. "Which specific genes and mutations did my testing show?" – Get the complete list
2. "What do these mutations mean for my prognosis and treatment options?" – Understand the clinical significance
3. "Will I need repeat testing, and if so, how often?" – Know your monitoring schedule
4. "Are there any targeted therapies available based on my mutations?" – Explore personalized treatment options
5. "What is my IPSS-M risk score, and what does that mean?" – Understand your overall risk category

Key Takeaway

Biomarker testing in MDS is comprehensive and multifaceted. According to the NCCN Guidelines, testing typically includes genetic sequencing, chromosome analysis, flow cytometry, and bone marrow examination. These tests work together to confirm your diagnosis, predict how your disease will progress, and guide your treatment plan.

Your oncologist will determine which specific tests are appropriate for YOUR situation and how often you need repeat testing based on your individual case.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.